Page last updated: 2024-09-03

c 1311 and Acute Myelogenous Leukemia

c 1311 has been researched along with Acute Myelogenous Leukemia in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Augustin, E; Beffinger, M; Konicz, S; Laskowska, K; Polewska, J; Skwarska, A; Wojtczyk, A	1

Other Studies

1 other study(ies) available for c 1311 and Acute Myelogenous Leukemia

Article	Year
Targeting of FLT3-ITD kinase contributes to high selectivity of imidazoacridinone C-1311 against FLT3-activated leukemia cells. Biochemical pharmacology, 2015, Jun-15, Volume: 95, Issue:4 Topics: Aminoacridines; Antineoplastic Agents; Apoptosis; Caspase 3; Cell Cycle; Cell Line, Tumor; Cell Survival; Cytarabine; Doxorubicin; Drug Synergism; Enzyme Activation; fms-Like Tyrosine Kinase 3; Humans; Inhibitor of Apoptosis Proteins; Leukemia, Myeloid, Acute; Mutation; Phosphorylation; RNA, Small Interfering; Signal Transduction; Survivin	2015

Article

Year

Targeting of FLT3-ITD kinase contributes to high selectivity of imidazoacridinone C-1311 against FLT3-activated leukemia cells.

Biochemical pharmacology, 2015, Jun-15, Volume: 95, Issue:4

Topics: Aminoacridines; Antineoplastic Agents; Apoptosis; Caspase 3; Cell Cycle; Cell Line, Tumor; Cell Survival; Cytarabine; Doxorubicin; Drug Synergism; Enzyme Activation; fms-Like Tyrosine Kinase 3; Humans; Inhibitor of Apoptosis Proteins; Leukemia, Myeloid, Acute; Mutation; Phosphorylation; RNA, Small Interfering; Signal Transduction; Survivin

2015